News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alcobra (ADHD) Discusses New Market Research And Updates On Recent Corporate Events At Investor Forum In New York City


7/17/2014 6:57:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TEL AVIV, Israel, July 17, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, held an Investor Forum on Tuesday, July 15, 2014 in New York City.

Dr. Craig Surman, MD, an expert in the management of adult ADHD, offered insights into the diagnosis and management of adult ADHD. Dr. Surman indicated that despite a decade of increased awareness and recognition, many adults with ADHD remain untreated or under treated. According to Dr. Surman, ADHD agents with novel effects, high tolerability, low risks, or whole-day coverage, could relieve a significant public health burden.

Alcobra's executive management team discussed an evidence-based overview of the commercial potential for its lead product, Metadoxine Extended Release (MDX) in ADHD based on recently completed research and analysis:

  • The ADHD market is worth more than $8 billion in the US. Adult ADHD accounts for half of the prescriptions and growing at an annual rate of around 10%
  • Physicians reacted very favorably to the product profile of MDX, and 36% of them indicate interest in MDX for their Adult ADHD patients
  • Alcobra projects annual sales of $2.2 billion for MDX in 2022

Management also provided an update on the ongoing development program for MDX and other corporate events:

  • Company completed enrollment in its Phase III Adult ADHD trial (AL012) and expects to report data by the end of this quarter
  • Company expects dosing of the first patient in its Phase IIb Fragile X Syndrome adolescents and adults trial (AL014) this month and data readout in Q4 of this year
  • Company expects dosing of first patient in its Phase II Pediatric ADHD program (AL015) in August and data readout in Q4 of this year
  • Company filed an F-3 shelf registration after becoming shelf-eligible in June. Dr. Yaron Daniely, the company's CEO confirmed that the company will not raise any capital before data readout of its Phase III Adult ADHD trial.

A webcast of the event and accompanying presentation materials are accessible on the Investor Relations section of Alcobra's website at www.alcobra-pharma.com.

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX (Metadoxine Extended Release (MG01CI)), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome. MDX has completed multiple Phase II studies in adults with ADHD and has completed enrollment in a Phase III study in adults with ADHD. The company expects to begin separate Phase IIb trials in pediatric ADHD and Fragile X Syndrome in 2014. The company was founded in 2008 and is headquartered in Tel Aviv, Israel. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.

Forward Looking Statements – This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Alcobra's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alcobra could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the projected annual sales of MDX, if MDX becomes an approved drug at all, timing of certain milestones in the Company's clinical program, including timing of dosing, and reporting results of clinical trials, if such trials commence and conclude as well as the company's intentions, plans or need to raise to raise any capital before data readout of its Phase III Adult ADHD program. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions or that historic results referred to in this press release would be interpreted differently in light of additional research and clinical and preclinical trials results. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Alcobra Ltd.'s Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 28, 2014, and in subsequent filings with the SEC. Except as otherwise required by law, Alcobra disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com

Alcobra Ltd. logo


Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Alcobra
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES